AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04700176
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered at 40 mg once weekly on days 1,8,15 for patients 75 years old and younger and at 20 mg once weekly on days 1,8,15 for patients older than 75.
Trial: NCT04948398
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Guselkumab 100 milligrams (mg) will be administered subcutaneously once every 8 weeks.
Trial: NCT05627245
Drug: Belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05627245
Drug: Tazemetostat
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05282953
Drug: KIO-301
RxNorm normalized name: KIO-301
DrugBank: KIO-301 (DB18465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KIO-301 intravitreal injection at ascending doses
Trial: NCT05324137
Drug: CM326
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CM326 injection
Trial: NCT05266534
Drug: Terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the efficacy of intramyometrial Terlipressin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
Trial: NCT05266534
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the efficacy of intramyometrial carbetocin injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
Trial: NCT05266534
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the efficacy of intramyometrial saline injection on hemoglobin level and decreasing blood loss in women undergoing open myomectomy
Trial: NCT05869903
Drug: Orforglipron
RxNorm normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04895761
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor all arms will receive
Trial: NCT06016387
Drug: Tucatinib 150 MG
RxNorm normalized name: tucatinib 150 MG
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tucatinib is a potent, selective, adenosine triphosphate-competitive small-molecule inhibitor of the receptor tyrosine kinase HER2. The molecular formula for tubatinib is C26H24N8O2 and it has a molecular weight of 480.52 g/mol.
Trial: NCT06016387
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MYL-1401O contains the active substance trastuzumab, which is an IgG1 monoclonal antibody. The molecular size of the intact molecule is around 148 kDa.~Each vial of MYL-1401O contains 150 mg of lyophilized proposed active biosimilar substance trastuzumab as well as 3.36 mg L-Histidine Hydrochloride, 2.16 mg L-Histidine, 115.2 mg sorbitol and 33.6 mg PEG-3350 (Macrogol 3350). Sorbitol and PEG-3350 substitute the α- trehalose dehydrate and polysorbate-20, which are used as excipients in the EU-approved and US-licensed Herceptin formulations.
Trial: NCT04716114
Drug: Salvage Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose cytarabine (LoDAC); azacytidine; homoharringtonine (HHT), cytarabine and aclarubicin (HAA) or fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) will be administered by subcutaneous (SC) and/or intravenous (IV) injections.
Trial: NCT04482712
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily administration of a dose of investigational drug for up to 4 weeks while hospitalized
Trial: NCT06379399
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks;
Trial: NCT05079698
Drug: 177Lu-PSMA-617
RxNorm normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion of 177Lu-PSMA-617 on Day 1 of treatment Cycles 1 and 2. PSMA PET utilizing either the 68Ga-PSMA-11 or 18F-DCFPyL tracer is acceptable. Patients should be restaged using the same tracer which was utilized to establish initial eligibility for the trial.
Trial: NCT06463587
Drug: Cladribine Low Dose
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive cladribine low dose in two courses separated by 4 weeks.
Trial: NCT06463587
Drug: Cladribine High Dose
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a total of cladribine high dose in two courses separated by 4 weeks.
Trial: NCT05085574
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg tablet, QID for 14 days
Trial: NCT04502407
Drug: Cisplatin Chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * High risk patients who are patients with positive margins, extranodal extension, or ≥5 positive lymph nodes will receive 5 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8, 15, 22, and 29 of radiation.~* All other patients will receive 3 cycles of weekly chemotherapy of cisplatin 40mg/m2 given intravenously (IV) on Days 1, 8 and 15 of radiation.
Trial: NCT05449548
Drug: Lenalidomide 10 mg
RxNorm normalized name: lenalidomide 10 MG
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects will be treated with lenalidomide 10mg/day with a regular follow-up of 12 weeks, followed by a 4-week observation after cessation of lenalidomide.
Trial: NCT05601700
Drug: Letrozole tablets
RxNorm normalized name: Letrozole Tablets
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATC: L02BG04
Trial: NCT05601700
Drug: carboplatin AUC 5 and paclitaxel 175 mg/m2
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ATC: L01XA02 and ATC: L01CD01 respectively
Trial: NCT05312008
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dose 40 IU in 1 ml; 2 booster doses of 24 IU in 0.6 mls each, spaced about 1 hour apart
Trial: NCT05904015
Drug: Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)
RxNorm normalized name: miconazole
DrugBank: Envafolimab (DB15769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin: Cisplatin: 75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 45Gy at a 95% PTV dose, with a single split dose of 3Gy, once a day, 5 times a week, for a total of 15 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable.
Trial: NCT05904015
Drug: Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)
RxNorm normalized name: miconazole
DrugBank: Envafolimab (DB15769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Envafolimab: 300mg SC d1,Q3W,2 cycles Cisplatin/carboplatin:Cisplatin:75 mg/m2 IV d1,Q3W ,2 cycles or Carboplatin:AUC=5/6 IV d1,Q3W,2cycles Etoposide: 100mg/m2 IV d1,Q3W ,2 cycles Radiotherapy: Provide a prescription dose of 60Gy at a 95% PTV dose, with a single split dose of 2Gy, once per day, 5 times per week, for a total of 30 times.~Envafolimab maintenance: 300mg,SC, d1. Q3W, up to 2 years or until PD or intolerable.
Trial: NCT05313620
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib 5 MG/day per clinical practice
Trial: NCT05313620
Drug: Infliximab Adalimumab y Golimumab
RxNorm normalized name: Golimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice or or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice.
Trial: NCT05067283
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per label
Trial: NCT05067283
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Per label
Trial: NCT05067283
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per label
Trial: NCT05067283
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per label
Trial: NCT01600807
Drug: Gemcitabine, Erlotinib, OSI-906
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
Trial: NCT01600807
Drug: Gemcitabine, Erlotinib
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
Trial: NCT05420727
Drug: Lu-177-ITG-PSMA-1
RxNorm normalized name: Lutetium dotatate Lu-177
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu-177-ITG-PSMA-1 treatment
Trial: NCT05509634
Drug: HR20013 for injection；dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
Trial: NCT05509634
Drug: fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: fosaprepitant dimeglumine for injection: Drug for preventing nausea and vomiting caused by chemotherapy~palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy
Trial: NCT00002119
Drug: WF10
RxNorm normalized name: Sodium hypochlorite
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000452
Drug: naltrexone (Revia)
RxNorm normalized name: naltrexone Oral Tablet [ReVia]
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04878406
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.
Trial: NCT04340232
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive a 2 mg oral dose of baricitinib.
Trial: NCT05577871
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: infusion of dexmedetomidine during the off pump coronary artery bypass grafting surgery
Trial: NCT06383767
Drug: Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eribulin, capecitabine, gemcitabine or vinorelbine
Trial: NCT04849026
Drug: Clozaril 100 mg (Clozapine)
RxNorm normalized name: clozapine 100 MG [Clozaril]
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 Doses/Day for 10 days
Trial: NCT04849026
Drug: WID-CLZ18
RxNorm normalized name: Black widow spider antivenom
DrugBank: Black widow spider antivenin (equine) (DB14113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Doses/Day for 10 days
Trial: NCT05267821
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: See information in arm/group descriptions
Trial: NCT04813926
Drug: Riociguat (Adempas, BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Follow clinical practice.
Trial: NCT05128942
Drug: Tildacerfont
RxNorm normalized name: Tildacerfont
DrugBank: Tildacerfont (DB18545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet formulation taken once daily in combination with glucocorticoid therapy.
Trial: NCT05983367
Drug: Ompenaclid
RxNorm normalized name: Ompenaclid
DrugBank: Ompenaclid (DB18819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ompenaclid (RGX-202-01)
Trial: NCT06265051
Drug: Tirofiban
RxNorm normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.
Trial: NCT05983367
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab
Trial: NCT06036914
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide will be administered via intravenous (IV) infusion at usual doses (twice the home dose of oral daily diuretic in furosemide equivalents) administered as 2 doses total within 24 hours.~Furosemide equivalents will be considered as follows (40 mg of intravenous furosemide = 1 mg oral bumetanide or 40 mg of torsemide or 80 mg of oral furosemide consistent with prior literature). The lowest dose of furosemide administered during the study will be 40 mg IV two times a day (BID) and the maximum dose will be 100 mg IV BID.
Trial: NCT04208464
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4mg daily for 24 weeks from baseline
Trial: NCT04208464
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4mg daily for 24 weeks starting after a 12-week treatment delay from baseline
Trial: NCT05802056
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06383390
Drug: Retatrutide
RxNorm normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05280548
Drug: Venglustat (GZ402671)
RxNorm normalized name: Venglustat
DrugBank: Venglustat (DB14966)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; Oral
Trial: NCT05280548
Drug: Agalsidase alfa
RxNorm normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Concentrate for solution for infusion; IV infusion
Trial: NCT05280548
Drug: Agalsidase beta (GZ419828)
RxNorm normalized name: Agalsidase Beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Powder for concentrate for solution for infusion; IV infusion
Trial: NCT05280548
Drug: Migalastat
RxNorm normalized name: Migalastat
DrugBank: Migalastat (DB05018)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Hard capsules; Oral
Trial: NCT06290141
Drug: riliprubart
RxNorm normalized name: Riliprubart
DrugBank: Riliprubart (DB18355)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: IV solution
Trial: NCT06290141
Drug: riliprubart
RxNorm normalized name: Riliprubart
DrugBank: Riliprubart (DB18355)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: SC solution
Trial: NCT06290141
Drug: IVIg
RxNorm normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Concentrate for solution for infusion (or any other formulation approved locally) Route of administration: IV solution
Trial: NCT04920682
Drug: Reversal of moderate neuromuscular blockade
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neostigmine 60 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)\> 0.4
Trial: NCT04920682
Drug: Reversal of superficial neuromuscular blockade
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4
Trial: NCT04920682
Drug: Two-step reversal
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neostigmine 30 mcg/kg when TOF = 3 and neostigmine 30 mcg/kg when TOF (T4 / T1)\> 0.4
Trial: NCT06392477
Drug: DR-0201
RxNorm normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DR-0201 is a bispecific antibody
Trial: NCT05909150
Drug: Sodium chloride solution 3,5%
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 150 mL HSS 3,5% intravenous twice daily for 3 days after heart transplantation.
Trial: NCT05909150
Drug: Sodium chloride solution 0,9%
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 150 mL NS 0,9% intravenous twice daily for 3 days after heart transplantation.
Trial: NCT04370145
Drug: Teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: severe cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
Trial: NCT04370145
Drug: Meropenem Injection
RxNorm normalized name: meropenem Injection
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cholangitis in control group were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
Trial: NCT06206733
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin will be administered as a minimum 2-hour IV infusion
Trial: NCT06206733
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.
Trial: NCT06333821
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40mg/m\^2
Trial: NCT06333821
Drug: placebo for Nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for Nimotuzumab 400mg
Trial: NCT05177133
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Oxaliplatin
Trial: NCT05177133
Drug: Retifanlimab
RxNorm normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV retifanlimab
Trial: NCT05034133
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab (IV 1000mg on day 1) with chemotherapy (Etoposide and Cisplatin) for 6 cycles
Trial: NCT04545554
Drug: Romosozumab
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive multiple doses of romosozumab via a SC injection.
Trial: NCT05251129
Drug: Atorvastatin 80 Mg Oral Tablet
RxNorm normalized name: ATORVASTATIN 80 mg ORAL TABLET
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher intensity statin
Trial: NCT04777331
Drug: Prasinezumab
RxNorm normalized name: Prasinezumab
DrugBank: Prasinezumab (DB14788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasinezumab will be administered as an IV infusion to participants Q4W.
Trial: NCT05546853
Drug: NP137
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NP137 will be administrated at the first day of each cycle (CnD1) of 14 days as an IV infusion at 9 or 14 mg/kg.
Trial: NCT05546853
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 85 mg/m²
Trial: NCT05546853
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan will be administreted at the first day of each cycle (CnD1) of 14 days as an IV infusion at 150 mg/m²
Trial: NCT05835895
Drug: transient immune-modulation
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT05835895
Drug: transient immune-modulation
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intra-articular injection
Trial: NCT04881838
Drug: Course A1 + Vin
RxNorm normalized name: Zygomycin A1
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;